A new effort to expand access to Gilead's twice-yearly PrEP drug to an additional 1 million people over the next three years doesn't go far enough, argue AVAC and Access Bridge.
highlights.www.linkedin.com/pulse/linksbridge-pharma...

Linksbridge Pharma: this week's highlights MSF blasts Gilead over lenacapavir sales Médecins Sans Frontières (MSF) is publicly slamming Gilead for its “outright refusal” to sell Yeztugo (lenacapavir) to the humanitarian organization. In an ope...

This week's issue highlights challenges along the path from drug innovation to patient access.
www.linkedin.com/pulse/linksb...

Linksbridge Pharma: this week's highlights Pharmaniaga wins Malaysia human insulin contract Pharmaniaga has scored its first contract to supply human insulin to Malaysian government hospitals, The Edge reported Wednesday. The three-year contra...

Pharmaniaga has landed a $70M, three-year contract to supply human insulin to Malaysia’s public hospitals, becoming the first local producer and potentially unseating supplier incumbents Biocon and Novo Nordisk.

www.linkedin.com/pulse/linksb...

Linksbridge Pharma: this week's highlights Vaxess abandons vaccines for GLP-1s Armed with a new name and $50 million in Series C funding, microarray patch specialist Vaxess—now Terrestrial Bio—is officially pivoting from vaccines to GLP-1s. Th...

The vaccine microarray patch field just got smaller. Needle-free vaccine specialist Vaxess—which raised millions for Covid, flu, measles-rubella and polio vaccines R&D—is pivoting to the lucrative GLP-1 space.
www.linkedin.com/pulse/linksb...

Linksbridge Pharma: this week's highlights Vaccine R&D: Nipah, chronic hep B and dengue news An mRNA-based Nipah vaccine co-developed by Moderna and the U.S.

In this week's highlights, we cover results of a Phase 1 trial of Moderna's Nipah virus vaccine. The jab uses a two-pronged approach: targeting both the attachment protein (as most Nipah candidates do) and the fusion protein (which may provide broader protection).

www.linkedin.com/pulse/linksb...

Linksbridge Pharma: this week's highlights BN drops Bio E, recruits SII for chikungunya jab access Bavarian Nordic has ditched a year-old chikungunya vaccine LMIC access deal with India’s Biological E and will tap Serum Institute of India inst...

Afrigen Biologics (Pty) Ltd is shifting to a nonprofit model as it seeks to exit business rescue in South Africa. The Cape Town-based biotech said the move will help reposition its focus on pandemic preparedness, innovation, R&D, and technology transfer.
www.linkedin.com/pulse/linksb...

Linksbridge Pharma: this week's highlights Simpler HAT treatment wins CHMP nod A single-dose oral treatment for gambiense human African trypanosomiasis (g-HAT) has scored a positive opinion from the EMA’s Committee for Medicinal Products for H...

A single-dose oral treatment is raising hopes that African countries could eliminate sleeping sickness. Acoziborole is the latest in a series of improvements in the treatment of sleeping sickness made possible in large part by the work of DNDI.
www.linkedin.com/pulse/linksb...

Linksbridge Pharma: this week's highlights Brazil continues push for pharma self-reliance A flurry of recent tie-ups between Brazilian pharma outfits and India- and South Korea-based companies aims to boost Brazil’s domestic cancer drug produc...

Brazil has emerged as a key player in regional manufacturing efforts in the Americas. This week, we explore a wave of new international partnerships that aim to boost the country’s domestic cancer drug production and strengthen its diagnostics position.
www.linkedin.com/pulse/linksb...

Linksbridge Pharma: this week's highlights AU Summit brings R&D, local manufacturing, and other pledges The African Union Summit in Addis Ababa last weekend saw the launch of a multipartner vaccine R&D initiative and more. ACHIEVE: Zambian Pre...

Whether you care about access to medicines, pandemic preparedness, clinical trial results for global health products, shake-ups at major agencies and pharma companies, or African manufacturing, this week's issue has something for everyone.

www.linkedin.com/pulse/linksb...

Linksbridge Pharma: this week's highlights U.S.

The U.S. FDA has refused to review the company's mRNA-based flu shot—with the notable twist of CBER chief Vinay Prasad personally signing off on the decision—while Mexico is moving to expand access to Moderna's mRNA vaccine portfolio.

www.linkedin.com/pulse/linksb...

Linksbridge Pharma: this week's highlights | Linksbridge Access to health products was a key theme in this week's highlights. Samsung Biologics and CEPI (Coalition for Epidemic Preparedness Innovations) are teaming up to accelerate equitable access to prote...

Access to health products was a key theme in this week's highlights. Samsung Biologics and CEPI are teaming up to accelerate equitable access to protein-based vaccines, BioNTech scored $25 million to develop its mRNA-based HIV vaccine for people in LMICs, and more.
www.linkedin.com/posts/linksb...

Linksbridge Pharma: this week's highlights U.S.

U.S. officials are trying to strongarm Gavi into removing vaccines from its portfolio that contain thimerosal, despite longstanding scientific consensus on the preservative's safety.

www.linkedin.com/pulse/linksb...

Linksbridge Pharma: this week's highlights USAID-backed HIV vaccine trial resurrected An African-led HIV vaccine trial that saw its USAID funding yanked away last year has been brought back from the brink of collapse and will start administeri...

After losing its USAID funding just days before it was set to launch an African-led HIV vaccine trial, the BRILLIANT Consortium has secured alternative financial support and will begin dosing in a scaled-down trial next week.
www.linkedin.com/pulse/linksb...

Linksbridge Pharma: this week's highlights SII exits chikungunya deal, enters Rift Valley agreement Serum Institute of India has exited one CEPI-backed vaccine production deal but joined another. On the last day of 2025, SII and Valneva said t...

CEPI is working with Valneva to find a new manufacturing partner in Asia for its chikungunya vaccine after the French pharma and Serum Institute of India scrapped their licensing deal for the shot.
www.linkedin.com/pulse/linksb...

Linksbridge Pharma: this week's highlights Moderna scores CEPI lifeline for pandemic flu shot More than six months after the U.S.

Our first issue of 2026 covers a wide range of vaccine-related updates. CEPI has awarded Moderna a $54 million lifeline for its pandemic flu shot, WHO published a report that paints a picture of the current global vaccine ecosystem, and more.

www.linkedin.com/pulse/linksb...

Linksbridge Pharma: this week's highlights Gonorrhea ‘turning point’: FDA OKs two new antibiotics Amid rising antibiotic resistance and a treatment landscape that hasn’t changed for decades, the U.S.

As big pharma walked away from antibiotic development, small resource-constrained biotechs have stepped up—but high costs have stalled progress. This week, we explore how a public-private partnership broke the gonorrhea antibiotic deadlock.
www.linkedin.com/pulse/linksb...

Linksbridge Pharma: this week's highlights CEPI-backed vaccines advance Oxford University has launched the world’s first Phase 2 clinical trial of a Nipah virus vaccine, CEPI announced Monday. The university will evaluate the ChAdOx1 NipahB ca...

While vaccine R&D plows forward, the financial and political foundations of global immunization continue to wobble.

www.linkedin.com/pulse/linksb...

Linksbridge Pharma: this week's highlights With dengue approval, Brazil expands vaccine leadership Brazilian approval last week of the world’s first single-dose dengue vaccine—the Butantan Institute’s Butantan-DV—represented a “historic achiev...

Brazil's vaccine leadership is gaining momentum. The country recently approved the world's first single-dose dengue vaccine, inked international supply and tech transfer deals, and is eyeing a stronger role in PAHO Revolving Funds.
www.linkedin.com/pulse/linksb...

Image of an Incepta R&D facility.

WHO prequalification of Incepta Pharmaceuticals's generic version of the Sayana Press, a 3-month injectable contraceptive that can be self-administered, potentially gives millions more people access to a discreet, convenient, affordable option: linksbridge-8615684.hs-sites-na2.com/this-weeks-r...

Stakeholder meeting report: Chikungunya virus – recent outbreaks, vaccine development and the way forward The International Vaccine Institute and Gorgas Institute (Gorgas Memorial Institute for Health Studies) organized the first Chikungunya Global Meeting…

🚨 New publication alert!

At the first Chikungunya Global Meeting in Panama City, stakeholders reviewed insights from recent outbreaks and discussed research priorities. Linksbridge's Katelyn Dinkel presented our chikungunya vaccine demand forecasting work and is an author of the meeting report:

Reports identify weakness in global pipeline for new antibiotics, diagnostics

The WHO says the pipeline for new antibiotics faces a "dual crisis" of scarcity and lack of innovation and that low-resource settings need simpler and faster diagnostic tests.

www.cidrap.umn.edu/a...

Linksbridge Pharma: this week's highlights Ghana ups wager on local vaccines Ghanaian President John Dramani Mahama has committed $50 million to “fast-track” the country’s vaccine production. The funds will support Ghana’s National Vaccine Ins...

This week's issue has something for everyone: news about African vaccine manufacturing, updates on lenacapavir access, a look at MNCs' retreat from U.K. investments, results from a malaria vaccine clinical trial, and more.

www.linkedin.com/pulse/linksb...

Linksbridge Pharma: this week's highlights PEPFAR recommits to lenacapavir access After threats to dismantle PEPFAR cast doubt over an access deal for Gilead’s lenacapavir PrEP drug, the U.S.

A Phase 3 trial has shown that the Zabdeno/Mvabea Ebola vaccine regimen induced antibody responses in pregnant women and their infants.
www.linkedin.com/pulse/linksb...

Linksbridge Pharma: this week's highlights Bedaquiline price cut pushes BPaLM under $300 Indian generics manufacturer Lupin has slashed the price of its tuberculosis drug bedaquiline by 30%, bringing the cost of a six-month course of the WHO-r...

This week's issue spotlights an impact analysis from our friends at MedAccess. The numbers are impressive: the nonprofit has reached 559 million people to date with vaccines, diagnostics and other health technologies supported by its agreements. www.linkedin.com/pulse/linksb...

Linksbridge Pharma: this week's highlights ‘Danger to health’: U.S.

In an about-face, the U.S. FDA has suspended Valneva’s chikungunya vaccine just weeks after lifting an earlier pause on use of the jab. More on this development and other pharma news important to global health in this week's issue.

www.linkedin.com/pulse/linksb...

Linksbridge Pharma: this week's highlights Phase 1 findings fuel nOPV trials in children Results from a first-in-human study of novel type 1 and type 3 oral poliovirus vaccines (nOPV1 and nOPV3, respectively) in adults are bolstering the case ...

Efforts to advance next-generation oral vaccines against polio type 1 and 3 got a boost this week with new Phase 1 trial data showing that the candidates performed similarly to their monovalent Sabin-strain comparators.
www.linkedin.com/pulse/linksb...

Linksbridge Pharma: this week's highlights WHO PQs first spatial emanators for vector control As insecticide resistance grows and shifting mosquito behavior threatens the effectiveness of long-standing vector control tools, WHO has prequalifie...

WHO has endorsed a new lifesaving tool in the fight against malaria. Two spatial emanator products from SC Johnson notched WHO prequalification this week, ushering in a new class of intervention for malaria vector control.
www.linkedin.com/pulse/linksb...

Linksbridge Pharma: this week's highlights BARDA abandons mRNA vaccine R&D In a move decried by public health leaders as shortsighted and baseless, the U.S.

BARDA is culling funding for mRNA vaccine R&D—a move public health officials say will hobble the country's capacity to combat the next pandemic. More on this development and other pharma news important to global health in this week's highlights.
www.linkedin.com/pulse/linksb...

Linksbridge Pharma: this week's highlights Non-invasive test detects infant meningitis An ultrasound-based test detected meningitis in neonates and infants with 94% accuracy, offering a potential non-invasive alternative to the traditional lumbar puncture diagnostic method, according to results of an international study published last week i

Lumbar puncture—an invasive technique with significant practical limitations—is the gold standard for diagnosing meningitis. Now, a non-invasive test may be on the horizon.
www.linkedin.com/pulse/linksb...

Linksbridge Pharma: this week's highlights Funding cuts loom over AIDS Society Conference Against the backdrop of a collapsed U.S.

The early days of this week's International AIDS Society Conference on HIV Science (IAS 2025) highlighted potentially epidemic-ending interventions and an urgent need for a reimagined funding landscape.
www.linkedin.com/pulse/linksb...